Filing Flows › Thermo Fisher Scientific (TMO) › Q3 2026 › vs Q3 2025
Thermo Fisher Scientific (TMO) Q3 2026 vs Q3 2025 (year over year)
Thermo Fisher Scientific's revenue rose $1.0B (+9%) from $11.1B in Q3 2025 to $12.1B in Q3 2026. The biggest changes: Laboratory Products and Biopharma Services +$893M (+15%); Analytical Instruments +$101M (+5%); Life Sciences Solutions +$85.0M (+4%). Operating margin 18.6% against 17.5% (+1.2 pts).
Thermo Fisher Scientific, Q3 2026: revenue $12.1B (+9% year over year), operating margin 18.6%, net earnings $1.7B, operating cash flow $2.5B. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 18.6% | 17.5% | +1.2 pts |
| Net margin | 14.2% | 14.6% | -0.3 pts |
| Free cash flow margin | 17.4% | 16.5% | +0.9 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Laboratory Products and Biopharma Services | $6.8B | $5.9B | $893M | +15% |
| Life Sciences Solutions | $2.3B | $2.2B | $85.0M | +4% |
| Analytical Instruments | $1.9B | $1.8B | $101M | +5% |
| Specialty Diagnostics | $1.1B | $1.2B | −$64.0M | -6% |
| Revenue | $12.1B | $11.1B | $1.0B | +9% |
| Operating profit | $2.3B | $1.9B | $322M | +17% |
| Costs & expenses | $9.9B | $9.2B | $693M | +8% |
| Pre-tax earnings | $2.1B | $1.8B | $253M | +14% |
| Other expense, net | $184M | $115M | $69.0M | +60% |
| Research & development | $348M | $346M | $2.0M | +0.6% |
| SG&A | $2.3B | $2.2B | $159M | +7% |
| Other operating costs | $7.2B | $6.7B | $532M | +8% |
| Net earnings | $1.7B | $1.6B | $106M | +7% |
| Income tax | $352M | $207M | $145M | +70% |
| Depreciation & amortization | $825M | $662M | $163M | +25% |
| Share-based compensation | $96.0M | $70.0M | $26.0M | +37% |
| Working capital & other | $98.0M | $114M | −$16.0M | -14% |
| Operating cash flow | $2.5B | $2.2B | $311M | +14% |
| Free cash flow (OCF − capex) | $2.1B | $1.8B | $278M | +15% |
| Capital expenditures | $437M | $404M | $33.0M | +8% |
Questions
How much did Thermo Fisher Scientific's revenue grow year over year in Q3 2026?
Thermo Fisher Scientific's revenue rose $1.0B (+9%) from $11.1B in Q3 2025 to $12.1B in Q3 2026.
What drove Thermo Fisher Scientific's revenue change in Q3 2026?
Laboratory Products and Biopharma Services +$893M (+15%); Analytical Instruments +$101M (+5%); Life Sciences Solutions +$85.0M (+4%).